Company Overview of Bio Products Laboratory Ltd
Bio Products Laboratory Ltd is engaged in the research and development, and manufacture of human blood plasma products. It offers normal intravenous immunoglobulin preparations for the treatment of patients who have no or very low levels of antibody production; products for primary and secondary immunodeficiency; idiopathic thrombocytopenic purpurafor; specific immunoglobulins; and products for Kawasaki disease. The company also provides products for Guillain-Barré Syndrome, a short-term inflammation of the nerves that control the arms and legs; Human Albumin that is used for the restoration and maintenance of circulating blood volume; and Factor VIII and Albumin products. It supply its plas...
Elstree, WD6 3BX
Founded in 1950
Key Executives for Bio Products Laboratory Ltd
Compensation as of Fiscal Year 2015.
Bio Products Laboratory Ltd Key Developments
Bio Products Laboratory, Limited Announces Enrollment of the First Subject in Phase III Clinical Trial to Evaluate New Subcutaneous Immunoglobulin Product for Patients with Primary Immunodeficiency
Sep 1 15
Bio Products Laboratory, Limited announced that the first subject has enrolled in SCIG03, a clinical trial evaluating the safety and pharmacokinetics of SubgamVF, 16% liquid immunoglobulin for the treatment of primary immunodeficiency. The trial, titled, 'A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of SubgamVF in Primary Immunodeficiency Diseases' (clinicaltrials.gov identifier, NCT01884311), will take place in the U.S. and will form the basis of a biologics license application for U.S. marketing authorization. The trial will enroll 35 patients with primary immunodeficiency and treat them for up to 26 weeks. The pharmacokinetics of SubgamVF will be assessed and will be compared to previous studies. Subgam-VF is a 16% immunoglobulin product made from human plasma specifically for subcutaneous use. The product is undergoing testing in the U.S. and has not been evaluated by the U.S. Food and Drug Administration.
Bio Products Laboratory Limited Announces Approval of Gammaplex for Pediatric Patient
Aug 6 15
Bio Products Laboratory Limited announced the approval of Gammaplex for pediatric patients two years of age and older who have primary humoral immunodeficiencies. The approval was based on data submitted to the U.S. Food and Drug Administration as part of a post-marketing commitment following approval of Gammaplex for replacement therapy in adults in 2009. Primary immunodeficiencies are a constellation of immune disorders that can negatively impact the body’s ability to fight infection. In some primary immunodeficiencies, the immune system does not manufacture adequate quantities of antibodies such as immune globulin G. This indication includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott Aldrich syndrome, and severe combined immunodeficiencies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries